ADMA Biologics Files 8-K

Ticker: ADMA · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1368514

Adma Biologics, Inc. 8-K Filing Summary
FieldDetail
CompanyAdma Biologics, Inc. (ADMA)
Form Type8-K
Filed DateDec 20, 2024
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$30 million, $62.5 million
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

ADMA Biologics filed an 8-K on 12/20/24, standard disclosure.

AI Summary

ADMA Biologics, Inc. filed an 8-K on December 20, 2024, reporting other events and financial statements. The filing does not contain specific details about new events, financial figures, or material agreements within the provided text.

Why It Matters

This filing indicates ADMA Biologics is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's status.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification without specific material events or financial data that would indicate immediate risk.

Key Players & Entities

  • ADMA BIOLOGICS, INC. (company) — Registrant
  • December 20, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 001-36728 (identifier) — SEC File Number
  • 56-2590442 (identifier) — IRS Employer Identification No.
  • 465 State Route 17, Ramsey, New Jersey 07446 (address) — Principal executive offices
  • (201) 478-5552 (phone_number) — Registrant's telephone number

FAQ

What specific events are being reported in this 8-K filing by ADMA Biologics?

The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not specify the details of these events or statements.

When was this 8-K filing submitted to the SEC?

The filing was submitted on December 20, 2024.

What is ADMA Biologics, Inc.'s principal executive office address?

The principal executive offices are located at 465 State Route 17, Ramsey, New Jersey 07446.

What is the SEC file number for ADMA Biologics, Inc.?

The SEC file number for ADMA Biologics, Inc. is 001-36728.

What is the SIC code for ADMA Biologics, Inc.?

The Standard Industrial Classification (SIC) code for ADMA Biologics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 10 · Accepted 2024-12-20 07:05:24

Key Financial Figures

  • $30 million — s release announcing that it has repaid $30 million from its original $62.5 million senior
  • $62.5 million — as repaid $30 million from its original $62.5 million senior secured term loan facility with

Filing Documents

01

Item 8.01 Other Events On December 20, 2024, ADMA Biologics, Inc. issued a press release announcing that it has repaid $30 million from its original $62.5 million senior secured term loan facility with Ares Capital Corporation and certain affiliated credit funds. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.

01

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 ADMA Biologics, Inc. Press Release, dated December 20, 2024. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. December 20, 2024 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President and Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.